VRDN Q1 2022 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$216,000-85.1% YoY

Gross Profit

-$18M-8115.7% margin

Operating Income

-$26M-11985.6% margin

Net Income

-$26M-11894.9% margin

EPS (Diluted)

$-0.98

QoQ Revenue Growth

+0.9%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$183M

Total Liabilities

$17M

Stockholders' Equity

$167M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$216,000	$1M	-85.1%
Gross Profit	-$18M	-$12M	-41.9%
Operating Income	-$26M	-$19M	-39.8%
Net Income	-$26M	-$18M	-39.2%

Revenue Segments

Collaboration Revenue

$200,000100%